---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-021904"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:35:50.906419+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting

## Summary
- Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.
- Phase 2 SHIMMER data showed 86% slowing of decline on NPI-12 vs placebo; no motor function worsening.
- No approved medications for DLB psychosis; traditional antipsychotics are contraindicated.
- Next study will use validated endpoints for neuropsychiatric symptoms; patients randomized to 100 mg zervimesine or placebo.
- Company expects to meet with FDA Division of Psychiatry by midyear 2026 to discuss the program.

## SEC filing metadata
- accession: 0001104659-26-021904
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465926021904/0001104659-26-021904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465926021904/tm267638d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-021904
- JSON: https://secwatch.observer/filing/0001104659-26-021904.json
- Plain text: https://secwatch.observer/filing/0001104659-26-021904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.